Understanding MBX-102: A New Drug for Diabetes
Author Information
Author(s): Holly J. Clarke, Francine Gregoire, Ma Fang, Robert Martin, Spring Zhao, Brian E. Lavan
Primary Institution: Metabolex, Inc.
Hypothesis
The study aims to evaluate the plasma protein binding of MBX-102 acid and the interspecies differences in free drug levels.
Conclusion
MBX-102 acid is highly protein-bound across species, with free drug levels being higher in rodents than in humans.
Supporting Evidence
- MBX-102 acid is highly bound (>98%) to human, rat, and mouse albumin.
- Free MBX-102 acid levels are higher in rodent plasma than in human plasma.
- PPAR-γ transactivation by MBX-102 acid was higher in rat and mouse serum than in human serum.
Takeaway
This study looks at how a new diabetes drug, MBX-102, binds to proteins in the blood and how this varies between humans and animals.
Methodology
The study used equilibrium dialysis and PPAR-γ transactivation assays to evaluate plasma protein binding and species differences.
Limitations
The study could not analyze serum concentrations higher than 10% in the reporter assay, which may affect the results.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website